natgillin/translations-raw huggingface dataset:
- If you have ever had interstitial lung disease (feeling a shortness of breath).
- če ste kdaj imeli intersticijsko bolezen pljuč (občutek kratke sape).
This may be reduced to a few weeks by taking certain medicines which speed up removal of Repso from your body.
To obdobje je mogoče skrajšati na nekaj tednov z jemanjem določenih zdravil, ki pospešijo odstranjevanje zdravila Repso iz telesa.
What Repso is and what it is used for
Kaj je zdravilo Repso in za kaj ga uporabljamo
Repso is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Zdravila Repso ni priporočljivo uporabljati za bolnike do 18. leta starosti, ker učinkovitost in varnost pri juvenilnem revmatoidnem artritisu (JRA) nista ugotovljeni (glejte poglavji 5.1 in 5.2).
Lactose monohydrate Povidone
Laktoza monohidrat Povidon
hypokalaemia, hyperlipidemia, hypophosphataemia
hipokaliemija, hiperlipidemija, hipofosfatemija
Repso belongs to a group of medicines called anti-rheumatic medicines.
Zdravilo Repso spada v skupino zdravil, ki jih imenujemo antirevmatična zdravila.
Repso tablets are tablets for oral use.
Tablete Repso so tablete za peroralno uporabo.
Most patients improved after discontinuation of Repso.
Večini bolnikov se je po prenehanju jemanja zdravila Repso stanje izboljšalo.
If you forget to take Repso
Če ste pozabili vzeti zdravilo Repso
Psoriatic arthritis is the combination of psoriasis and arthritis.
Psoriatični artritis je kombinacija psoriaze in artritisa.
In either case it should be confirmed by a blood test that Repso has been sufficiently removed from your body and you should then wait for at least another month before you become pregnant.
V obeh primerih je treba s krvno preiskavo potrditi, da se je zdravilo Repso dovolj odstranilo iz telesa, potem pa morate počakati vsaj še en mesec, preden zanosite.
The unbound fraction of A771726 is about 0.62 %.
Nevezana frakcija A771726 je približno 0,62 %.
What you need to know before you take Repso
Kaj morate vedeti, preden boste vzeli zadravilo Repso
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske Agencije za zdravila http://www.ema.europa.eu/.
If you are pregnant or become pregnant while taking Repso, the risk of having a baby with serious birth defects is increased.
Če ste noseči ali zanosite med jemanjem zdravila Repso, je povečano tveganje, da se rodi otrok z resnimi prirojenimi okvarami.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Izdaja zdravila je le pod omejenimi pogoji in na recept (glej Priloga I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
The risk of their occurrence can be increased in patients with a history of interstitial lung disease.
Tveganje za njihov nastanek se lahko poveča pri bolnikih z intersticijsko boleznijo pljuč v anamnezi.
- If you have liver problems.
- če imate kakršnekoli težave z jetri.
Other medicines and Repso
Druga zdravila in zdravilo Repso
Repso is used to treat adult patients with active rheumatoid arthritis or with active psoriatic arthritis.
Zdravilo Repso se uporablja za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom ali aktivnim psoriatičnim artritisom.
The concentration may be expected to decrease below 0.02 mg/l about 2 years after stopping the treatment with leflunomide.
Znižanje koncentracije pod 0,02 mg/l je mogoče pričakovati približno 2 leti po prenehanju zdravljenja z leflunomidom.
Effect on organic anion transporter 3 (OAT3) substrates
Vpliv na substrate prenašalca organskih anionov 3 (OAT3)
If the test confirms that you are pregnant, your doctor may suggest treatment with certain medicines to remove Repso rapidly and sufficiently from your body, as this may decrease the risk to your baby.
Če test potrdi, da ste noseči, vam bo zdravnik morda predlagal zdravljenje z določenimi zdravili, ki hitro in uspešno odstranijo zdravilo Repso iz vašega telesa, ker to lahko zmanjša tveganje za otroka.
Results of animal fertility studies have shown no effect on male and female fertility, but adverse effects on male reproductive organs were observed in repeated dose toxicity studies (see section 5.3).
Rezultati študij plodnosti pri živalih niso pokazali učinka na plodnost pri moških in ženskah, pač pa so v študijah toksičnosti ponavljajočih se odmerkov opazili neželene učinke na moške reproduktivne organe (glejte poglavje 5.3).
Repso can occasionally cause some problems with your blood, liver, lungs, or nerves in your arms or legs.
Občasno lahko zdravilo Repso povzroči nekatere krvne, jetrne, pljučne težave ali težave z živci v rokah in nogah.
paraesthesia, headache, dizziness, peripheral neuropathy
parestezije, glavobol, omotica, periferna nevropatija
For women receiving leflunomide treatment and who wish to become pregnant, one of the following procedures is recommended in order to ascertain that the foetus is not exposed to toxic concentrations of A771726 (target concentration below 0.02 mg/l):
Pri ženskah, ki prejemajo leflunomid in želijo zanositi, je treba z enim od naslednjih postopkov zagotoviti, da plod ne bo izpostavljen toksični koncentraciji A771726 (ciljna koncentracija je pod 0,02 mg/l):
marginal (reversible) decreases in sperm concentration, total sperm count and rapid
mejno (reverzibilno) znižanje koncentracije semenčic, celotnega števila semenčic in
Rare: Not known:
Redki: Neznani:
- If you switch to another medicine to treat your rheumatoid arthritis or if you have recently taken medicines that may be harmful to your liver or blood, your doctor may advise you to take certain medicines to speed up the removal of Repso from your body or may closely monitor you when you start taking Repso.
- če ste prej jemali druga zdravila za zdravljenje revmatoidnega artritisa ali če ste pred kratkim jemali zdravila, ki lahko škodujejo vašim jetrom ali krvi, vam bo zdravnik morda predlagal, da vzamete zdravila, ki bodo pospešila izločanje zdravilo Repso iz vašega telesa ali vas bo natančno spremljal ob začetku jemanja zdravila Repso.
In a study with radiolabelled 14C-leflunomide in three healthy volunteers, no unchanged leflunomide was detected in plasma, urine or faeces.
V študiji z radioaktivno označenim 14C-leflunomidom pri 3 zdravih prostovoljcih v plazmi, urinu ali blatu niso našli nespremenjenega leflunomida.
- The other ingredients are (see section 2 “Repso contains lactose”)
- Pomožne snovi so (glejte poglavje 2 "Zdravilo Repso vsebuje laktozo")
Some vaccinations should not be given while taking Repso, and for a certain amount of time after stopping treatment.
Določenih cepiv se med uporabo zdravila Repso in določen čas po koncu tega zdravljenja ne sme uporabljati.
Titanium dioxide (E171) Hypromellose (E464) Macrogol 400
Titanov dioksid (E171) Hipromeloza (E464) Makrogol 400
A771726 displaced ibuprofen, diclofenac and tolbutamide but the unbound fraction of these drugs is only increased by 10 % to 50 %.
A771726 je izpodrinil ibuprofen, diklofenak in tolbutamid, vendar se je nevezana frakcija teh zdravil zvečala samo za 10 do 50 %.
- If you develop swollen spongy gums, ulcers, and loose teeth (an infectious mouth disease known as ulcerative stomatitis) then you should contact your doctor who may advise you to stop taking Repso.
- če se pri vas pojavijo gobaste dlesni, razjede in izguba zob (infekcijska ustna bolezen, znana kot ulcerativni stomatitis), obvestite svojega zdravnika, ki vam bo morda svetoval prenehanje jemanja zdravila Repso.
Repso is contraindicated in pregnancy (see section 4.3).
Zdravilo Repso je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
The pharmacokinetics of A771726 following oral administration of leflunomide have been investigated in 73 pediatric patients with polyarticular course Juvenile Rheumatoid Arthritis (JRA) who ranged in age from 3 to 17 years.
Farmakokinetiko A771726 po peroralni uporabi leflunomida so raziskali pri 73 pediatričnih bolnikih, starih od 3 do 17 let, ki so imeli juvenilni revmatoidni artritis (JRA) s poliartikularnim potekom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 March 2011
Datum pridobitve dovoljenja: 14. 3. 2011 Datum zadnjega podaljšanja:
The efficacy of leflunomide in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Učinkovitost leflunomida so pri zdravljenju revmatoidnega artritisa dokazali v 4 kontroliranih preskušanjih (1 v II.
If you suspect that you are pregnant while taking Repso or in the two years after you have stopped treatment, you must contact your doctor immediately for a pregnancy test.
Če med jemanjem zdravila Repso ali v dveh letih po koncu zdravljenja posumite, da ste zanosili, morate o tem nemudoma obvestiti svojega zdravnika in opraviti nosečnostni test.
If you or someone else swallows a lot of the tablets all together, or if you think a child has swallowed any of the tablets, contact your nearest hospital casualty department or your doctor immediately.
Če ste vzeli večji odmerek zdravila Repso, kot bi smeli Če ste vi ali kdo drug, pogoltnil več tablet naenkrat, ali če mislite, da je otrok pogoltnil tableto, se nemudoma obrnite na oddelek nujne pomoči najbližje bolnišnice ali obvestite svojega zdravnika.
Women of childbearing potential must not take Repso without using reliable contraceptive measures, and they must use reliable contraceptive measures up to 2 years after treatment.
Ženske v rodni dobi ne smejo jemati zdravila Repso, če ne uporabljajo zanesljive kontracepcijske zaščite in morajo uporabljati zanesljivo kontracepcijsko zaščito do 2 leti po zdravljenju.
In case you forget to take a dose, take it as soon as you remember.
Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite, razen če ni že blizu čas za naslednjega.
Rare cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported in patients receiving leflunomide among other immunosuppressants.
Poročali so o redkih primerih progresivne multifokalne levkoencefalopatije (PML) bolnikih, ki so prejemali leflunomid poleg ostalih zdravil z imunosupresivnim delovanjem.
If both plasma concentrations are below 0.02 mg/l, and after a waiting period of at least 3 months, the risk of foetal toxicity is very low.
Če je ta koncentracija v obeh primerih manjša od 0,02 mg/l in po vsaj 3-mesečnem čakalnem obdobju, je tveganje toksičnosti za plod zelo majhno.
What Repso is and what it is used for What you need to know before you take Repso How to take Repso
Kaj je zdravilo Repso in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Repso Kako jemati zdravilo Repso Možni neželeni učinki
Colestyramine given orally at a dose of 8 g three times a day for 24 hours to three healthy volunteers decreased plasma levels of A771726 by approximately 40 % in 24 hours and by 49 % to 65 % in 48 hours.
Holestiramin, uporabljen peroralno v odmerku 8 g trikrat na dan 24 ur je pri treh zdravih prostovoljcih znižal plazemsko koncentracijo A771726 za približno 40 % v 24 urah in za 49 % do 65 % v 48 urah.
Tell your doctor if you plan to become pregnant after stopping treatment with Repso, as you need to ensure that all traces of Repso have left your body before trying to become pregnant.
Povejte svojemu zdravniku, če nameravate po prenehanju zdravljenja z zdravilom Repso zanositi, saj se morate, preden poskušate zanositi, prepričati, da v telesu ni več ostankov zdravila Repso.
- Severe infections (including sepsis), which may be fatal.
hude okužbe, vključno s sepso, ki je lahko usodna.
The results of a population pharmacokinetic analysis of these trials have demonstrated that pediatric patients with body weights ≤ 40 kg have a reduced systemic exposure (measured by Css) of A771726 relative to adult rheumatoid arthritis patients (see section 4.2).
Rezultati populacijske farmakokinetične analize teh preskušanj so pokazali, da je pri pediatričnih bolnikih s telesno maso ≤ 40 kg sistemska izpostavljenost A771726 (merjena s Css) manjša kot pri odraslih bolnikih z revmatoidnim artritisom (glejte poglavje 4.2).
If a patient taking Repso develops a peripheral neuropathy, consider discontinuing Repso therapy and performing the drug elimination procedure (see section 4.4).
Če bolnik med jemanjem zdravila Repso razvije periferno nevopatijo, je potrebno razmisliti o ukinitvi terapije z zdravilom Repso in o izvajanju postopka za eliminacijo zdravila (glejte poglavje 4.4).
Titanium dioxide (E171) Polydextrose (E1200) Hypromellose (E464) Triethyl citrate (E1505) Macrogol 8000
Titanov dioksid (E171) Polidekstroza (E1200) Hipromeloza (E464) Trietilcitrat (E1505) Makrogol 8000
Repso tablets should be swallowed whole with plenty of water.
Tablete zdravila Repso pogoltnite celo in z veliko vode.
Men wishing to father a child should contact their doctor who may advise them to stop taking Repso and take certain medicines to remove Repso rapidly and sufficiently from their body.
Moški, ki želijo zaploditi otroka, se morajo posvetovati z zdravnikom, ki jim bo morda svetoval, naj nehajo jemati zdravilo Repso in vzamejo določena zdravila za hitro in uspešno izločanje zdravila Repso iz telesa.
The use of leflunomide with antimalarials used in rheumatic diseases (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive agents including Tumour Necrosis Factor alpha-Inhibitors has not been adequately studied up to now in randomised trials (with the exception of methotrexate, see section 4.5).
Uporaba leflunomida z antimalariki, ki se uporabljajo pri revmatičnih boleznih (npr. s klorokinom ali hidroksiklorokinom), intramuskularnim ali peroralnim zlatom, D-penicilaminom, azatioprinom in drugimi imunosupresivnimi zdravili, vključno z zaviralci tumorje nekrotirajočih faktorjem alfa, doslej v randomiziranih preskušanjih ni bila raziskana (z izjemo metotreksata, glejte poglavje 4.5).
In responders, this response was maintained during 48 weeks.
Pri bolnikih, ki so se odzvali na zdravljenje, se je ta odziv ohranjal 48 tednov (glejte poglavje 4.2).
As soon as skin and/or mucosal reactions are observed which raise the suspicion of such severe reactions, Repso and any other possibly associated treatment must be discontinued, and a leflunomide washout procedure initiated immediately.
Čim se na koži in/ali sluznici pojavijo reakcije, ki zbujajo sum na takšne hude reakcije, je treba prekiniti uporabo zdravila Repso in drugih zdravil, ki bi jih lahko povzročila, in takoj začeti postopek izpiranja.
Repso is contraindicated in patients with severe hypoproteinaemia or impairment of liver function (see section 4.3).
Zdravilo Repso je kontraindicirano pri bolnikih s hudo hipoproteinemijo ali okvarjenim delovanjem jeter (glejte poglavje 4.3).
The usual starting dose is 100 mg once a day for 3 days.
Običajni začetni odmerek zdravila Repso je 100 mg enkrat na dan prve tri dni.
In such cases re-exposure to leflunomide is contra-indicated (see section 4.3).
Ponovna uporaba leflunomida je kontraindicirana (glejte poglavje 4.3).
Following concomitant administration of a single dose of leflunomide to subjects receiving multiple doses of rifampicin (non-specific cytochrome P450 inducer) A771726 peak levels were increased by approximately 40 %, whereas the AUC was not significantly changed.
Po sočasni aplikaciji enega samega odmerka leflunomida osebam, ki so prejemale ponavljajoče se odmerke rifampicina (nespecifičnega induktorja citokroma P450), so se najvišje koncentracije A771726 zvišale za približno 40 %, AUC pa se ni pomembno spremenila.
- If you are male and wish to father a child. As it cannot be excluded that Repso passes into semen, reliable contraception should be used during treatment with Repso.
- če ste moški in želite zaploditi otroka.Obstaja možnost, da se zdravilo Repso izloča v semensko tekočino, zato mora bolnik med zdravljenjem z zdravilom Repso uporabljati zanesljivo kontracepcijo.
Each film-coated tablet contains 97.25 mg of lactose monohydrate and 3.125 mg anhydrous lactose.
Ena filmsko obložena tableta vsebuje 97,25 mg laktoze monohidrata in 3,125 mg brezvodne laktoze.
• The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate).
• O ugotovljenem tveganju za sinergistično hepato ali hemato toksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (diseasemodifying antirheumatic drug (DMARD) zdravili (na primer metotreksat).
Leflunomide 20 mg/day was significantly superior to placebo in reducing the symptoms of arthritis in patients with psoriatic arthritis: the PsARC (Psoriatic Arthritis treatment Response Criteria) responders were 59 % in the leflunomide group and 29.7 % in the placebo group by 6 months (p < 0.0001).
Leflunomid v odmerku 20 mg/dan je simptome artritisa pri bolnikih s psoriatičnim artritisom zmanjšal značilno bolj kot placebo: bolnikov, ki so se odzvali po merilih PsARC (Psoriatic Arthritis treatment Response Criteria; merila odziva na zdravljenje psoriatičnega artritisa), je bilo do 6. meseca med prejemniki leflunomida 59 % in med prejemniki placeba 29,7 % (p < 0,0001).
Each film-coated tablet contains 194.5 mg of lactose monohydrate and 6.25 mg anhydrous lactose.
Ena filmsko obložena tableta vsebuje 194,5 mg laktoze monohidrata in 6,25 mg brezvodne laktoze.
Administration of activated charcoal (powder made into a suspension) orally or via nasogastric tube (50 g every 6 hours for 24 hours) has been shown to reduce plasma concentrations of the active metabolite A771726 by 37 % in 24 hours and by 48 % in 48 hours.
Dokazano je, da uporaba aktivnega oglja (prašek, pripravljen v suspenziji) peroralno ali po nazogastrični sondi (50 g na 6 ur v 24 urah) zniža plazemsko koncentracijo aktivnega presnovka A771726 za 37 % v 24 urah in za 48 % v 48 urah.
interstitial lung disease (including interstitial pneumonitis), which may be fatal
intersticijska bolezen pljuč (vključno z intersticijsko pljučnico), ki je lahko usodna.
If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, these may be continued after starting leflunomide.
Če bolnik že prejema nesteroidna protivnetna zdravila (NSAIDs - nonsteroidal anti inflammatory drugs), kortikosteroide ali oboje, jih lahko po začetku jemanja leflunomida uporablja še naprej.
increased hair loss, eczema, rash (including maculopapular rash), pruritus, dry skin
zvečano izpadanje las, ekcem, izpuščaji (vključno makulopapularni izpuščaji), pruritus, suha koža
This metabolite is responsible for essentially all the in vivo activity of leflunomide.
Ta je odgovoren za praktično vso aktivnost leflunomida in vivo.
If you are already taking non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, you may continue to use these after starting Repso.
Če že jemljete nesteroidna protivnetna zdravila (NSAID) ali kortikosteroide ali oboje, lahko z njimi nadaljujete tudi po začetku uporabe zdravila Repso.
The efficacy of leflunomide was demonstrated in one controlled, randomised, double blind study 3L01 in 188 patients with psoriatic arthritis, treated at 20 mg/day.
Učinkovitost leflunomida je dokazala kontrolirana, randomizirana dvojno slepa študija 3L01 pri 188 bolnikih s psoriatičnim artritisom.
Effect of leflunomide on other medicinal products
Vpliv leflunomida na druga zdravila:
The ACR (American College of Rheumatology) response rates in study YU203 were 27.7 % for placebo, 31.9 % for 5 mg, 50.5 % for 10 mg and 54.5 % for 25 mg/day.
Deleži odziva po ACR (American College of Rheumatology) so bili v študiji YU203 27,7 % na placebo, 31,9 % na leflunomid 5 mg, 50,5 % na leflunomid 10 mg in 54,5 % na leflunomid 25 mg/dan.
In the phase III trials, the ACR response rates for leflunomide 20 mg/day versus placebo were 54.6 % versus 28.6 % (study MN301), and 49.4 % versus 26.3 % (study US301).After 12 months with active treatment, the ACR response rates in leflunomide patients were 52.3 % (studies MN301/303), 50.5 % (study MN302) and 49.4 % (study US301), compared to 53.8 % (studies MN301/303) in sulphasalazine patients, 64.8 % (study MN302), and 43.9 % (study US301) in methotrexate patients.
Po 12 mesecih aktivnega zdravljenja so bili deleži odzivov po ACR pri bolnikih na leflunomidu 52,3 % (študiji MN301/303), 50,5 % (študija MN302) in 49,4 % (študija US301) v primerjavi s 53,8 % (študiji MN301/303) pri bolnikih na sulfasalazinu ter 64,8 % (študija MN302) oz. 43,9 % (študija US301) pri bolnikih na metotreksatu.
• active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD),
("disease-modifying antirheumatic drug" (DMARD)),
Therefore, it is not recommended to drink alcohol during treatment.
Med zdravljenjem z zdravilom Repso zato ni priporočljivo pitje alkohola.
Uncommon side effects (may affect up to 1 in 100 people) - Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness
Občasni neželeni učinki (prizadanejo lahko največ 1 od 100 ljudi) - zmanjšanje števila rdečih krvnih celic, kar lahko povzroči bledico kože in slabotnost ali zasoplost (anemija)
Do not take Repso when you are breast-feeding, as leflunomide passes into the breast milk.
Ne jemljite zdravila Repso, če dojite, saj leflunomid lahko prehaja v mleko.
UAB “Sicor Biotech” Eesti filiaal Tel: +372 661 0801
UAB “Sicor Biotechˮ Eesti filiaal Tel: +372 661 0801
Interstitial lung disease, as well as rare cases of pulmonary hypertension have been reported during treatment with leflunomide (see section 4.8).
Med zdravljenjem z leflunomidom so poročali o intersticijski bolezni pljuč, pa tudi o redkih primerih pljučne hipertenzije (glejte poglavje 4.8).
Concomitant administration of hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) is not advisable.
Sočasna uporaba hepatotoksičnih ali hematotoksičnih imunomodulirajočih antirevmatičnih zdravil (npr. metotreksata) ni priporočljiva.
Effect of other medicinal products on leflunomide
Vpliv drugih zdravil na leflunomid:
severe anaphylactic/anaphylactoid reactions, vasculitis, including cutaneous
hude anafilaktične/anafilaktoidne reakcije, vaskulitis, vključno s kožnim nekrotizirajočim vaskulitisom
The doctor that starts you on Repso and supervises you while you are on it should be experienced in the treatment of rheumatoid arthritis and psoriatic arthritis.
Zdravnik, ki je pri vas začel zdravljenje z zdravilom Repso in vas spremlja med zdravljenjem, mora biti izkušen v zdravljenju revmatoidnega in psoriatričnega artritisa.
The symptoms include inflammation of joints, swelling, difficulty moving, pain and patches of red, scaly skin (skin lesions).
Simptomi aktivnega psoriatičnega artritisa vključujejo vnetje sklepov, zatekanje, težko premikanje, bolečine in rdeče, luskaste površine na koži (lezije kože).
taste disturbances
motnje okusa
• Physician Leaflet The Physician Leaflet should contain the following key messages:
Navodilo za zdravnika mora vsebovati naslednje informacije:
- For psoriatic arthritis: 20 mg once daily.
• za zdravljenje aktivnega psoriatičnega artritisa: 20 mg zdravila Repso enkrat na dan.
In case of severe haematological reactions, including pancytopenia, Repso and any concomitant myelosuppressive treatment must be discontinued and a leflunomide washout procedure initiated.
V primeru hudih hematoloških reakcij, vključno s pancitopenijo, je treba prekiniti uporabo zdravila Repso in morebitnih drugih mielosupresivnih zdravil ter začeti postopek izpiranja leflunomida.
Swallow tablets whole.
Pogoltnite celo tableto.
Psoriatic arthritis
Psoriatrični artritis
Do not use this medicine after the expiry date that is stated on the outer carton, blister or tablet container after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji ovojnini, pretisnem omotu ali vsebniku za tablete poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
It will take 4 to 6 weeks before you feel an improvement in your condition.
Do opaznega izboljšanja stanja lahko mine 4-6 tednov.